India Drug Makers Ordered To Supply Drug-Cost Data Or Face Penalties
This article was originally published in PharmAsia News
India's drug-pricing regulator has given pharmaceutical companies operating in the country 10 days to furnish data on their costs for essential drugs or face prosecution.
You may also be interested in...
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.